1 2	
3	<b>Cardiac Troponin Fragmentation After Heavy Physical Exercise</b>
4	The MaraCat2 Study
5	
6	
7	K. E. Juhani Airaksinen, MD, PhD <sup>1</sup> ; Tuomas Paana, MD, PhD <sup>1</sup> ; Tapio Hellman, MD, PhD <sup>2</sup> ; Tuija
8	Vasankari, MSc <sup>1</sup> ; Selma Salonen, MSc <sup>3</sup> ; Tuulia Tuominen, MSc <sup>3</sup> , Konsta Teppo, MD, PhD <sup>1</sup> , Samuli
9	Jaakkola. MD, PhD <sup>1</sup> ; Olli J. Heinonen, MD, PhD <sup>4</sup> , Saara Wittfooth, PhD <sup>3</sup>
10	
11	<sup>1</sup> Heart Center, Turku University Hospital and University of Turku, Turku, Finland
12	<sup>2</sup> Kidney Center, Turku University Hospital and University of Turku, Finland
13	<sup>3</sup> Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland
14	<sup>4</sup> Paavo Nurmi Centre & Unit for Health and Physical Activity, University of Turku, Turku, Finland
15	Short title: Troponin fragmentation after marathon race and MI
16	Word count: 3368
17	Corresponding author:
18	Prof. K.E. Juhani Airaksinen, MD, PhD
19	Heart Center, Turku University Hospital, Turku, Finland
20	Postal address: Hämeentie 11, PO Box 52, 20521 Turku
21	Email: juhani.airaksinen@tyks.fi

23

# 24 Abstract

## 25 Background:

Elevations of commercial cardiac troponin T (total cTnT) levels are common after strenuous
exercise, but there is limited information on whether the troponin composition differs from
myocardial infarction (MI).

#### 29 Methods:

Troponin composition was analyzed in heparin plasma samples taken from 45 runners <1 h after

marathon race and from 45 patients with Type 1 MI <12 h after the pain onset. The concentration of

32 long molecular forms of cTnT (long cTnT) was measured with a novel upconversion luminescence

assay, total cTnT was measured with a commercial high-sensitivity cTnT assay, and the ratio of

34 long to total cTnT (troponin ratio) was determined.

# 35 **Results:**

36 Total cTnT exceeded the upper reference limit (>14 ng/l) in 37 (82%) runners. The median total and

long cTnT concentrations and the troponin ratio were higher (113 ng/l vs. 25 ng/l, 57 ng/l vs. 4.1

ng/l, and 0.36 vs. 0.17, respectively) in patients with MI than in marathon runners (p < 0.001 for all

comparisons). Troponin ratio decreased (r = -0.497, p < 0.001) in marathon runners and increased (r

40 = 0.466, p = 0.001) in patients with MI with increasing troponin release. In the receiver operating

41 characteristics curve analyses of all subjects with cTnT release >14ng/l and those with 15-100 ng/l,

42 long cTnT showed good predictive power with the area under the curve 0.969 (CI95% 0.939-1.000)

43 and 0.937 (95% CI, 0.877–0.996) in discriminating marathon runners from MI patients. The

44 respective values for total cTnT were 0.892 (CI95% 0.823-0.960) and 0.778 (95% CI, 0.656–

**45** 0.901).

46 Conclusions:

47	In contrast to Type 1 MI, after strenuous exercise only a small fraction of circulating cTnT exists as
48	intact cTnT or long molecular fragments. The difference in troponin composition could be of
49	diagnostic value when evaluating post-exercise cTnT elevations in subjects with chest complaints.
50	
51 52	Registration: URL: <u>https://www.clinicaltrials.gov;</u> Unique identifier: NCT06000930
53	
54	Key words: troponin, exercise, marathon, athlete, myocardial infarction, myocardial injury
55	

56		
57	Non-stand	ard Abbreviations and Acronyms
58		
59	MI	Myocardial infarction
60	cTnT	Cardiac troponin T
61	mAb	monoclonal antibodies
62	aar	amino acid residues
63	AUC	Area under the curve
64	ROC	Receiver operating characteristics
65		

# 66 Clinical Perspective

# 68 What Is New?

69	•	Short cardiac troponin T (cTnT) fragments were the predominant form of cTnT release after				
70		marathon race among 45 runners in contrast to 45 patients with Type 1 myocardial infarction				
71		(MI) where intact cTnT and longer fragments are more commonly found in the circulation				
72		during the early hours after the attack also in patients with comparable troponin levels.				
73	•	The proportion of short cTnT components decreased (r = -0.497, p < 0.001) in marathon				
74		runners and increased ( $r = 0.466$ , $p = 0.001$ ) in patients with MI with increasing troponin				
75		release.				
76	Wha	t Are the Clinical Implications?				
76 77	Wha •	t Are the Clinical Implications? The principle of the novel immunoassay could be applied on automated platforms to allow				
		-				
77		The principle of the novel immunoassay could be applied on automated platforms to allow				
77 78		The principle of the novel immunoassay could be applied on automated platforms to allow implementation in clinical care and separate benign cTnT elevations after strenuous exercise				

85

86 87

Cardiac troponins are in a key role in the diagnosis of acute myocardial infarction (MI).<sup>1</sup> Minor 88 cardiac troponin elevations are common also after strenuous exercise, causing diagnostic challenges 89 when associated with chest discomfort.<sup>2,3</sup> The exact mechanisms of cardiac troponin rise after 90 strenuous physical activity remains ill-defined, but according to a small gel filtration 91 chromatography study, the released cardiac troponin T (cTnT) in this condition seems to be 92 predominantly in the form of small molecules.<sup>4</sup> Temporary increase in permeability of cell 93 membranes may allow the leakage of these smaller cytosolic troponin fragments to circulation. 94 Importantly, the current commercial high-sensitivity cTnT test detects the small and long troponin 95 fragments and the intact cTnT containing the stable central part of the cTnT molecule and is called 96 97 here the total cTnT assay. In a Proof-of-Principle study, we developed a simple time-resolved immunofluorometric assay 98 99 based on europium chelate labels for the measurement of long cTnT molecules. The assay showed a high accuracy in discriminating between cTnT elevations in MI and end-stage renal failure.<sup>5</sup> In the 100 present study protocol, we compared the characteristics of troponin release after a marathon race 101

and Type 1 MI using an improved version of the long cTnT test and the commercial total cTnT test.

103 Methods

## 104 *Patients and samples*

A total of 45 recreational runners (31 male) aged 28-75 (median 35) years participating in the Paavo
Nurmi Marathon 2023 in Turku were recruited to the MaraCat2 Study (ClinicalTrials.gov Identifier:
NCT06000930) with an open email invitation. Eighteen participants finished the full marathon and
27 the half-marathon. None of the patients had a history of coronary artery disease. All participants
gave a lithium-heparin plasma sample within 60 min after finishing the race.

110	A control group of 45 patients (36 male) with acute MI (25 ST elevation MI) were recruited among
111	patients admitted to Heart Centre of Turku University Hospital (ClinicalTrials.gov Identifiers:
112	NCT04465591 and NCT05858112). Coronary angiography was performed in all included patients
113	to confirm culprit lesion and the MI diagnosis and all included patients were treated with primary or
114	urgent percutaneous coronary intervention. Only patients with a delay less than 12 hours from
115	symptom onset to lithium-heparin plasma sample collection and estimated glomerular filtration rate
116	$> 30 \text{ mL/min}/1.73 \text{m}^2$ were included.
117	All participants provided a written informed consent. The study complies with the Declaration of
118	Helsinki as revised in 2013 and the study protocol was approved by the Medical Ethics Committee
119	of the Hospital District of Southwest Finland.
120	The samples were analyzed fresh for total cTnT. In separate sample tubes the plasma was aliquoted
121	after centrifugation and stored at $-70$ °C until analysis by the long cTnT assay.
122 123	Analytical methods
	Analytical methods The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion
123 124	
123 124 125	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion
123 124 125 126	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup>
123 124 125 126 127	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup> The anti-cTnT monoclonal antibodies (mAb) and human cardiac troponin ITC-complex used as a
123 124 125 126 127 128 129	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup> The anti-cTnT monoclonal antibodies (mAb) and human cardiac troponin ITC-complex used as a calibrator were obtained from HyTest Ltd (Turku, Finland). The capture antibody (7E7 mAb) and
123 124 125 126 127 128	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup> The anti-cTnT monoclonal antibodies (mAb) and human cardiac troponin ITC-complex used as a calibrator were obtained from HyTest Ltd (Turku, Finland). The capture antibody (7E7 mAb) and the tracer antibody (1C11 mAb) bind to amino acid residues (aar) 223–242 and 174–190 of cTnT,
123 124 125 126 127 128 129 130 131	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup> The anti-cTnT monoclonal antibodies (mAb) and human cardiac troponin ITC-complex used as a calibrator were obtained from HyTest Ltd (Turku, Finland). The capture antibody (7E7 mAb) and the tracer antibody (1C11 mAb) bind to amino acid residues (aar) 223–242 and 174–190 of cTnT, respectively. The C-terminal region of cTnT between these two epitopes (aar 190–223) contains
123 124 125 126 127 128 129 130	The novel highly sensitive two-step heterogenous sandwich-type immunoassay using upconversion luminescence for signal production was used for the detection of long molecular forms of cTnT. <sup>6</sup> The anti-cTnT monoclonal antibodies (mAb) and human cardiac troponin ITC-complex used as a calibrator were obtained from HyTest Ltd (Turku, Finland). The capture antibody (7E7 mAb) and the tracer antibody (1C11 mAb) bind to amino acid residues (aar) 223–242 and 174–190 of cTnT, respectively. The C-terminal region of cTnT between these two epitopes (aar 190–223) contains several cleavage sites and thus, the ability of the assay to detect long forms of cTnT is based on

Total cTnT was analyzed using a commercial high-sensitivity cTnT assay (Elecsys hs-cTnT, Roche
Diagnostics GmbH, Mannheim, Germany). For this assay, the limits of detection and quantitation

are 3 ng/l and 13 ng/l, respectively. The ratio of long cTnT forms/total cTnT (troponin ratio) was
used as the measure of troponin fragmentation.<sup>5</sup>

#### 139 Statistical analysis

140

Continuous variables are reported as median  $(25^{th} - 75^{th} \text{ percentiles})$  and categorical variables as 141 counts (percentage). Mann-Whitney U test was used for group comparisons. Chi-squared test and 142 Fisher's exact test were used for categorical variables as appropriate. Correlation between 143 continuous variables was estimated using the Spearman's test. Linear regression analysis was used 144 to identify factors significantly relating to total and long cTnT levels and their ratio in marathon 145 runners and MI patients. All predictors with a p value < 0.1 in univariate analysis were included in 146 147 the final regression model. Receiver operating characteristics (ROC) curve analyses were performed to estimate the area under the curve (AUC) to measure the discriminative capacity of cTnT, long 148 cTnT and the troponin ratio between marathon runners and MI patients. Additional analyses were 149 150 performed to assess their discriminative capacity between marathon runners and MI patients with cTnT levels ranging from 15 to 100 ng/l, the cTnT level considered to be most important in the 151 differential diagnosis between MI and exercise-induced cTnT release. All tests were two-sided, and 152 the limit of significance was set at p < 0.05. Sigmaplot 15 (Inpixon, California) was used for the 153 comparison of ROC curves and IBM SPSS Statistics software version 26.0 was used to perform all 154 other analyses. 155

- 156
- 157 158
- 159 **Results**
- 160

```
161 Total cTnT, long cTnT, and troponin ratio in marathon runners and patients with myocardial
162 infarction
```

None of the runners reported cardiac symptoms after the race. Total cTnT exceeded the upper
reference limit (>14 ng/l) in 37 (82%) runners with a median concentration of 25.0 ng/l (range 7-63)

ng/l). Median long cTnT concentration was 4.1 ng/l (range 1-8.4 ng/l) (Table 1). The total and long 165 cTnT levels were higher after full marathon than after half-marathon (33 (25-47 ng/l) vs. 20 (11-27 166 ng/l) and 5.6 (3.6-7.6 ng/l) vs. 3.3 (2.2-4.7 ng/l), p = 0.002 for both comparisons). Troponin ratio 167 decreased significantly (r = -0.497, p < 0.001) with increasing total cTnT release (Figure 1). 168 Both the total cTnT and long cTnT concentrations as well troponin ratio were higher (p < 0.001 for 169 all) in MI patients than in marathon runners (Table 1). In contrast to the marathon runners, in MI 170 patients troponin ratio increased significantly (r = 0.466, p = 0.001) with increasing total cTnT 171 release (Figure 1). Total cTnT and long cTnT concentrations and troponin ratio were not related to 172 the time delay from pain onset to blood sampling or any clinical features of the MI patients listed in 173 Table 1. 174

175

# 176 Diagnostic performance of long cTnT measurement

177 To assess the diagnostic value of long cTnT, we compared the troponin composition of the 37 marathon runners having elevated total cTnT levels (>14 ng/l) with all MI patients and with a 178 179 subgroup of MI patients (N=22) having total cTnT less than 100 ng/l. In both of these analyses, total cTnT, long cTnT and troponin ratio were higher (p<0.001) in patients with MI (Figure 2). 180 In the ROC curve analyses, both the total and long cTnT showed excellent predictive power in 181 discriminating marathon runners from MI patients with a small but statistically significance 182 difference in favor of long cTnT, with respective AUCs of 0.892 (CI95% 0.823-0.960) and 0.969 183 (CI95% 0.939-1.000) (p = 0.012). The cutoff point of 8.2 ng/l for the long cTnT ratio showed a 184 sensitivity of 86.7% ja specificity of 97.3% in separating runners and MI patients (Figure S1). 185 When restricting the analysis only in subjects with total cTnT concentration from 15 to 100 ng/l, the 186 respective AUC values for total cTnT and long cTnT were 0.778 (95% CI, 0.656-0.901) and 0.937 187 (95% CI, 0.877–0.996) (p = 0.007). 188

#### 191 **Discussion**

192 193

190

As expected, the majority of runners had post-race cTnT levels above the rule-in criteria for the diagnosis of acute MI and the troponin release was more marked after running the full marathon. Most importantly, we showed that short cTnT fragments are the predominant form of cTnT release after marathon race in contrast to Type 1 MI where longer and intact cTnT forms are more commonly found in the circulation during the early hours after MI also in patients with comparable troponin levels.

The present findings on troponin fragmentation after exercise are in line with the gel filtration 200 201 chromatography study by Vroeman et al showing in 10 runners with a postrace cTnT exceeding 70 ng/l that this cTnT release concerned only secondary cTnT fragments of which the N-terminal and 202 C-terminal ends of the protein were cleaved off.<sup>4</sup> The results with our sensitive immunoassay 203 technique confirmed this in a larger group of runners and with less profuse troponin release. 204 Importantly, we could show that the magnitude of long cTnT release remained at a low level in spite 205 206 of increasing release of total cTnT. The current finding on smaller troponin fragments as the predominant component of circulating cTnT after exercise is similar to the troponin composition 207 seen in patients with end-stage renal failure, although the long cTnT levels in renal patients were 208 slightly lower than the present concentrations after exercise.<sup>5,7</sup> In MI, intact and longer forms of 209 troponin were the predominant form of troponin release in patients with extensive myocardial 210 damage, which is in line with previous reports on small groups of patients with large ST elevation 211 MI.<sup>5,8,9</sup> As a novel finding, our sensitive test showed that the troponin composition was related to 212 the magnitude of myocardial injury and the cTnT release included more smaller components in 213 214 patients with milder myocardial injury.

Proposed mechanisms for exercise-induced cTnT elevations include increased cell membrane
 permeability or cellular release of proteolytic troponin degradation products during exercise.<sup>3</sup>

Enhanced myocyte turnover, necrosis, and apoptosis are among other potential mechanisms of 217 cardiac troponin release. The role of temporary increase in cell membrane permeability is supported 218 by small cardiac magnetic resonance imaging studies which have detected myocardial oedema, 219 transient increases in mean diffusivity and extracellular volume with a positive correlation to 220 troponin release after marathon race.<sup>10,11,12</sup> 221 In clinical practice problems may arise when subjects present with chest pain to the emergency 222 department shortly after strenuous exercise and have elevated troponin levels. Electrocardiogram is 223 often normal, but in some cases athlete's heart may complicate the interpretation. The present 224 observations on marked differences in troponin composition between Type 1 MI and exercise-225 226 induced benign troponin release could be helpful in the diagnostic workup of the patients in the

227 "grey zone" of mildly elevated troponin release.

Earlier research on troponin fragmentation has employed gel filtration chromatography, Western blotting and mass spectrometry, techniques that are too complicated for clinical use.<sup>4,8,9</sup> The low analytical sensitivity of these methods is another obstacle for clinical applications.<sup>4,9</sup> In contrast, our immunoassay approach is a significantly more sensitive method for the analysis of cTnT fragmentation. Importantly, the principle of our assay could be applied on automated platforms to allow implementation in clinical care to improve the accuracy and rapidity of laboratory diagnostics of MI.

Our study group was quite small and the troponin release after the race was less than in many previous reports. We did not collect blood samples before the race, but based on earlier research, chronic elevation of troponins in these healthy subjects is unlikely.<sup>2,3</sup> In some patients the long cTnT concentrations were higher than the total cTnT values in our study. This is likely due to differences in the calibration of the assays. It should be noted, that fragmentation of troponins

- seems to be a continuous process after MI.<sup>5,13</sup> Longer delays between MI symptom onset and
- sampling are likely to dilute the observed differences in troponin composition.
- 242 In conclusion, this novel highly sensitive long cTnT immunoassay shows that the troponin release
- 243 after strenuous exercise is composed mainly of smaller troponin fragments. The test holds promise
- that measuring long cTnT forms could help to separate benign cTnT elevations after strenuous
- exercise from those of acute MI in a single sample with better accuracy than the commercial high-
- sensitivity cTnT test.
- 247

# 249 Acknowledgements

We would like to thank Jaana Rosenberg from the University of Turku for providing us with the upconverting nanoparticle labels.

252

#### 253 Sources of Funding

- 254 This work was supported by the Finnish Foundation for Cardiovascular Research, Helsinki,
- 255 Finland, Clinical Research Fund (EVO) of Turku University Hospital, Turku, Finland, the Finnish
- 256 Society of Clinical Chemistry, Helsinki, Finland, the Turku University Foundation, Turku, Finland,
- and the Varsinais-Suomi Regional Fund of the Finnish Cultural Foundation, Turku, Finland.
- 258 The funding organizations had no role in the design and conduct of the study; collection,
- 259 management, analysis, and interpretation of the data; preparation, review, or approval of the

260 manuscript; and decision to submit the manuscript for publication.

261

### 262 Disclosures

- 263 K.E. Juhani Airaksinen: Research grants from the Finnish Foundation for Cardiovascular Research
- and Clinical Research Fund of Turku University Hospital, Turku, Finland. Lectures for Astra
- 265 Zeneca, Bayer, Boehringer Ingelheim, Pending patent application WO2023187258 (A1) ASSAY

266 FOR LONG FORMS OF CARDIAC TROPONIN T

- 267 Tuomas Paana: Lectures for Astra Zeneca
- 268Tuija Vasankari: Pending patent application WO2023187258 (A1) ASSAY FOR LONG FORMS
- 269 OF CARDIAC TROPONIN T
- 270 Selma Salonen: None
- 271 Tuulia Tuominen: None

- 272 Tapio Hellman: Lectures for AstraZeneca, Astellas and GSK, Pending patent application
- 273 WO2023187258 (A1) ASSAY FOR LONG FORMS OF CARDIAC TROPONIN T
- 274 Konsta Teppo: Research grants from The Finnish Foundation for Cardiovascular Research, Aarne
- and Aili Turunen Foundation, The Finnish Medical Foundation, The Finnish Foundation for Alcohol
- 276 Studies and the Finnish State Research Funding.
- 277 Samuli Jaakkola: Lectures for Amgen, Boehringer Ingelheim, BMS Pfizer
- 278 Olli J. Heinonen: None
- 279 Saara Wittfooth: Research grants from the Finnish Society of Clinical Chemistry, the Turku
- 280 University Foundation and the Varsinais-Suomi Regional Fund of the Finnish Cultural Foundation,
- and the Finnish Foundation for Cardiovascular Research. Research funding from Business Finland,
- official Finnish government agency for trade and investment promotion, innovation funding, travel
- promotion and talent attraction. Pending patent application WO2023187258 (A1) ASSAY FOR

284 LONG FORMS OF CARDIAC TROPONIN T

#### 286

#### 287 References

288	1.	Thygesen K,	Alpert JS,	Jaffe AS, et al.	Fourth universal	definition of m	vocardial infarction
-----	----	-------------	------------	------------------	------------------	-----------------	----------------------

- 289 (2018). Eur Heart J. Published online August 2018. doi:10.1093/eurheartj/ehy462
- 290 2. Paana T, Jaakkola S, Bamberg K, et al. Cardiac troponin elevations in marathon runners.
- 291 Role of coronary atherosclerosis and skeletal muscle injury. The MaraCat Study. *Int J*
- 292 *Cardiol*. 2019;295:25-28. doi:10.1016/j.ijcard.2019.08.019
- 293 3. Aengevaeren VL, Baggish AL, Chung EH, et al. Exercise-Induced Cardiac Troponin
- 294 Elevations: From Underlying Mechanisms to Clinical Relevance. *Circulation*.

295 2021;144(24):1955-1972. doi:10.1161/CIRCULATIONAHA.121.056208

- 4. Vroemen WHM, Mezger STP, Masotti S, et al. Cardiac Troponin T: Only Small Molecules
  in Recreational Runners After Marathon Completion. *J Appl Lab Med*. 2019;3(5):909-911.
- doi:10.1373/JALM.2018.027144
- Airaksinen KEJ, Aalto R, Hellman T, Vasankari T, Lahtinen A, Wittfooth S. Novel Troponin
   Fragmentation Assay to Discriminate Between Troponin Elevations in Acute Myocardial
   Infarction and End-Stage Renal Disease. *Circulation*. 2022;146(18):1408-1410.
- 302 doi:10.1161/CIRCULATIONAHA.122.060845

Salonen SM, Tuominen TJK, Raiko K, Vasankari T, Aalto R, Hellman T, Lahtinen S, Soukka
 T, Airaksinen KEJ, Wittfooth S. Highly sensitive immunoassay for long forms of cardiac
 troponin T using upconversion luminescence. *Clin Chem* (in press)

- 306 7. Mingels AMA, Cardinaels EPM, Broers NJH, et al. Cardiac troponin T: Smaller molecules in
   307 patients with end-stage renal disease than after onset of acute myocardial infarction. *Clin*
- 308 *Chem.* 2017;63(3):683-690. doi:10.1373/clinchem.2016.261644

309	8.	Cardinaels EPM, Mingels AMA,	Van Rooij T. Coll	linson PO, Prinzen FW	V. Van Dieijen
	<b>.</b>		,		, , , , , , , , , , , , , , , , , , , ,

- 310 Visser MP. Time-dependent degradation pattern of cardiac troponin T following myocardial
- infarction. *Clin Chem.* 2013;59(7):1083-1090. doi:10.1373/clinchem.2012.200543
- 312 9. Vylegzhanina A V., Kogan AE, Katrukha IA, et al. Full-size and partially truncated cardiac
- troponin complexes in the blood of patients with acute myocardial infarction. *Clin Chem.*
- 314 2019;65(7):882-892. doi:10.1373/clinchem.2018.301127
- 10. Aengevaeren VL, Froeling M, Hooijmans MT, et al. Myocardial Injury and Compromised
- 316 Cardiomyocyte Integrity Following a Marathon Run. *JACC Cardiovasc Imaging*.
- 317 2020;13(6):1445-1447. doi:10.1016/J.JCMG.2019.12.020
- Eijsvogels TMH, Aengevaeren VL. Exercise-induced myocardial damage is associated with
  cardiac edema and dysfunction: adding another piece to the troponin puzzle. *Eur J Appl*
- 320Physiol. Published online July 26, 2023. doi:10.1007/s00421-023-05282-5
- 12. Gaudreault V, Tizon-Marcos H, Poirier P, et al. Transient Myocardial Tissue and Function
- 322 Changes During a Marathon in Less Fit Marathon Runners. *Can J Cardiol*.
- 323 2013;29(10):1269-1276. doi:10.1016/j.cjca.2013.04.022
- 13. Vylegzhanina A V., Kogan AE, Katrukha IA, et al. Full-size and partially truncated cardiac
- troponin complexes in the blood of patients with acute myocardial infarction. *Clin Chem*.
- 326 2019;65(7):882-892. doi:10.1373/clinchem.2018.301127

327


329

# **Table 1**. Clinical Characteristics and Total and Long cTnT and Their Ratio (Troponin Ratio) in the

331 Study Groups.

	Marathon	MI patients	р
	runners (n =45 )	(n = 45)	
Age, y	35 (31-61)	69 (57-76)	< 0.001
Female gender	14 (31.1)	9 (20.0)	0.334
Hypertension	0 (0)	25 (55.6)	<0.001
Diabetes	1 (2.2)	10 (22.2)	0.007
Heart failure	0 (0)	1 (2.2)	1.0
Atrial fibrillation	1 (2.2)	5 (11.1)	0.203
Creatinine, μg/l	101 (89-124)	79 (67-89)	< 0.001
Total cTnT, ng/l	25.0 (16-36)	113 (43-1000)	< 0.001
Long cTnT, ng/l	4.1 (2.4-5.8)	57 (13-854)	< 0.001
Troponin ratio	0.17 (0.11-	0.36 (0.24-	<0.001
	0.24)	1.31)	


Values are medians (25<sup>th</sup> – 75<sup>th</sup> percentile) for continuous variables and n (%) for categorical
variables. MI, myocardial infarction; Total cTnT, commercial high-sensitivity cardiac troponin T;
long cTnT, long molecular forms of cTnT.



335

336


Figure 1. Concentrations of long forms of cTnT (long cTnT) in relation to the magnitude of
total cTnT release. The share of long cTnT of total cTnT (troponin ratio) decreased (r = -0.497, p
<0.001) with increasing total cTnT release in marathon runners and increased (r = 0.466, p =0.001)</li>
in patients with myocardial infarction (MI).



343

## 344 Figure 2. Immunoassay for long cTnT forms to discriminate between marathon runners with

- 345 total cTnT >14ng/L and patients with MI. Total cTnT, long cTnT forms (Long cTnT), and
- troponin ratio (ratio of long cTnT forms to total cTnT) in marathon runners with total cTnT >14ng/l
- 347 and in patients with myocardial infarction (MI) and <12-hour delay between symptom onset and
- blood sampling (Upper Panel) and in a subgroup of patients with total cTnT 15-100 ng/l (Lower
- 349 Panel).



# 357 **Figure S1.**

- 358 Receiver operating characteristic curves depicting the discriminative capacity of long cTnT
- 359 (full line) and total cTnT (dotted line) between marathon runners with cTnT release >14ng/l
- and MI patients. (all patients: AUCs of 0.892 [CI95% 0.823-0.960] and 0.969 [CI95% 0.939-
- 361 1.000] [panel A]; and MI patients with total cTnT release 15-100 ng/L: 0.778 [95% CI, 0.656–
- 362 0.901] and 0.937 [95% CI, 0.877–0.996] [panel B]). AUC indicates area under the curve; MI, acute
- 363 Type 1 myocardial infarction with time from pain onset to blood sample < 12 hours; cTnT, cardiac
- 364 troponin T.